Trial Profile
A Phase II Study of Bortezomib (Velcade ) Administered as a Single Agent in Metastatic Non-Clear Cell Renal Cell Carcinoma (RCC) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Carcinoma; Renal cancer
- Focus Therapeutic Use
- 18 Apr 2012 Actual patient number changed from 3 to 4 as reported by ClinicalTrials.gov.
- 17 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 May 2010 Actual patient number (3) added as reported by ClinicalTrials.gov.